Sign inJoin waitlistJoin the waitlist

TV

Timothy Voorhees

Physician · Ohio State University College of Medicine

Credentials: · · · · · ·

History

Ohio State University College of Medicine
2021–Present

UNC Hospitals
2020–2022
Hematology and Medical Oncology
University of North Carolina Hospitals
2017–2020
Internal Medicine
Ohio State University Hospital
2014–2017
Ohio State University College of Medicine
2010–2014

Research

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Blood · 2022 · 81 citations
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Blood Advances · 2020 · 71 citations
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Blood Advances · 2022 · First of 17 authors · 47 citations

Narendranath Epperla
26 papers
Robert Baiocchi
19 papers
YS
Yazeed Y Sawalha
18 papers
Beth Christian
17 papers
David Bond
17 papers
Kami Maddocks
16 papers
Lapo Alinari
15 papers
Audrey Sigmund
12 papers · 1 as a fellow
Marcos de Lima
11 papers
Natalie Grover
11 papers
Walter Hanel
11 papers
Jonathan Brammer
10 papers

Grants

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disorders: Identifying Viral and Host Variables to Predict Risk and Therapeutic Responses
National Cancer Institute · R01
PI · $367K · Ohio State University
2026–2031

Clinical trials

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Principal investigator · Recruiting · Phase 1
Ohio State University Comprehensive Cancer Center
2026–2027
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Principal investigator · Recruiting · Phase 1
Timothy Voorhees
2025–2026
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Principal investigator · Completed
Ohio State University Comprehensive Cancer Center
2023–2025
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Principal investigator · Recruiting · Phase 2
Timothy Voorhees
2023–2027